Selective Transarterial Embolization of Gastro-Entero Pancreatic (GEP) Neuroendocrine Tumors (NET) with Advanced Locoregional Disease and/or Liver Metastases Abstract #1888

Introduction: Selective transarterial embolization(TAE) and chemoembolization(TACE),are alternative options to systemic therapies in patients with GEP-NET G1/G2 with advanced locoregional disease and/or unresectable liver metastases
Aim(s): We report clinical-Rx outcomes in 7 patients who received TAE/TACE from Oct 2015 to Oct 2016,to assess the potential benefit of this treatment
Materials and methods: TAE was performed using beads 200 microns in diameter,loaded with 150 mg doxorubicin in TACE.Tumor necrosis was evaluated according to modified RECIST using computed tomography 1 month after treatment
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Concepcion Blanco
Keywords: TACE, TAE, GEP-NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#528 Trans-Arterial Embolization (TAE) is the Best Locoregional Treatment Option for Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Trans-arterial embolization (TAE) and chemoembolization (TACE) have been shown to be effective in patients (pts) with liver metastases (LM) from gastroenteropancreatic neuroendocrine tumor (GEP NET). TAE and TACE goal is to reduce blood flow to the tumor resulting in ischemia and necrosi.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Michela Del Prete
Keywords: TAE, TACE, NET
#882 Gene Expression Characterization of Gastroenteropancreatic Neuroendocrine Tumors [GEPNETS: Gastrointestinal and Pancreatic NETs (GINETs and pNETs)] and Their Correlation with Clinical Factors and Tumor Behavior
Introduction: GEP-NETs are a heterogenous group of tumors with different molecular backgrounds and clinical outcome.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: J A Díaz Pérez
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis
Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Angel Diaz Perez
#1133 Prognosis of Stage IV Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) According to the WHO Classification and the Primary Tumor Location
Introduction: WHO classification of GEP-NET is used to predict prognosis, yet survival within each grade shows wide variation. We hypothesized that primary tumor location may be partially responsible of this variability.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: PhD Paula Jiménez-Fonseca